SCHEMBL18485991

SCHEMBL18485991

O=Cc1cc(=O)[nH]c2cc(N[C@H](C=O)[C@H](O)[C@@H](O)[C@@H](O)CO)ccc12

nearest known ligand 0.37

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 14/20 0.37
▸ KDM4E B2RXH2 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ GLA P06280 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18486054 1.00 AR (0.37) ARKDM4EALDH1A1GLAGAA
SCHEMBL18486112 0.93 AR (0.36) AR
SCHEMBL18486026 0.93 AR (0.36) AR
SCHEMBL18486021 0.90 KDM4E (0.42) ARKDM4EALDH1A1GLAGAA
SCHEMBL18486134 0.90 KDM4E (0.42) ARKDM4EALDH1A1GLAGAA
SCHEMBL18486057 0.90 AR (0.36) AR
SCHEMBL18486040 0.90 AR (0.36) AR
SCHEMBL18486059 0.90 AR (0.36) AR
SCHEMBL18486043 0.90 AR (0.36) AR
SCHEMBL18486039 0.87 AR (0.37) AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180238899-A1 NOVEL GLUCOSE DERIVATIVE, AND CELL IMAGING METHOD AND IMAGING AGENT USING SAID DERIVATIVE HIROSAKI UNIVERSITY (JP) 2018-08-23 — — US disclosed
US-10001487-B2 Glucose derivative, and cell imaging method and imaging agent using said derivative HIROSAKI UNIVERSITY (JP) 2018-06-19 — — US disclosed
US-20170122955-A1 NOVEL GLUCOSE DERIVATIVE, AND CELL IMAGING METHOD AND IMAGING AGENT USING SAID DERIVATIVE HIROSAKI UNIVERSITY (JP) 2017-05-04 — — US disclosed
EP-3130596-A1 NOVEL GLUCOSE DERIVATIVE, AND CELL IMAGING METHOD AND IMAGING AGENT USING SAID DERIVATIVE Hirosaki University (JP) 2017-02-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170122955-A1 NOVEL GLUCOSE DERIVATIVE, AND CELL IMAGING METHOD AND IMAGING AGENT USING SAID DERIVATIVE SLC2A4, SLC2A1, UGGT1 AR 4179/4885KDM4E 2736/4885ALDH1A1 494/4885
US-10001487-B2 Glucose derivative, and cell imaging method and imaging agent using said derivative SLC2A4, SLC2A1, G6PD AR 3967/4885KDM4E 2987/4885ALDH1A1 455/4885
US-20180238899-A1 NOVEL GLUCOSE DERIVATIVE, AND CELL IMAGING METHOD AND IMAGING AGENT USING SAID DERIVATIVE SLC2A4, SLC2A1, UGGT1 AR 4170/4885KDM4E 2730/4885ALDH1A1 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback